Every pharmaceutical container-closure system—glass vials, elastomeric rubber stoppers, pre-filled syringes, plastic IV bags, and single-use bioprocess bags—is in direct contact with the drug product. Over time, chemical compounds can migrate from the packaging materials into the medication. Regulatory agencies mandate comprehensive Extractables and Leachables (E&L) Validation under USP ⟨1663⟩ (Extractables) and USP ⟨1664⟩ (Leachables). This engineering guide details analytical screening protocols using GC-MS, LC-MS, and ICP-MS, calculating the Analytical Evaluation Threshold (AET), and performing toxicological risk assessments.
In This Guide
- 1. The E&L Lifecycle: Extractables vs. Leachables Defined
- 2. USP ⟨1663⟩ & ⟨1664⟩ Regulatory Frameworks
- 3. Analytical Instrumentation: GC-MS, LC-MS, and ICP-MS Screening
- 4. Calculating the Analytical Evaluation Threshold (AET)
- 5. Toxicological Risk Assessments & Safety Thresholds (PQRI Guidelines)
- 6. E&L Validation Acceptance Parameter Matrix
- 7. Interactive Analytical Evaluation Threshold (AET) Calculator
- 8. Extractables & Leachables Validation Protocol Checklist
- 9. Top FDA Warning Letters & Filing Deficiencies for E&L
1. The E&L Lifecycle: Extractables vs. Leachables Defined
Understanding the distinction between extractables and leachables is critical for pharmaceutical packaging engineers and analytical chemists:
Extractables vs. Leachables Study Workflow
- Extractables: Chemical compounds that can be forced out of a packaging material under exaggerated laboratory conditions (aggressive solvents like hexane or isopropanol, high heat, and extended time).
- Leachables: Chemical entities that actually migrate into the drug product under normal manufacturing, storage, and shelf-life conditions. These are what patients ultimately ingest or inject.
Extractables and Leachables: Handbook of Validation
The definitive engineering manual for designing E&L studies, selecting aggressive extraction solvents, and interpreting GC-MS/LC-MS spectral data.
Check Price on Amazon →LC-MS/MS Method Development in Pharma
Master chromatographic separation, mass spectrometry tuning, and trace-level identification of unknown migrating chemical compounds.
Check Price on Amazon →2. USP ⟨1663⟩ & ⟨1664⟩ Regulatory Frameworks
Global pharmacopeias provide clear standards governing packaging interaction testing:
- USP ⟨1663⟩ (Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems): Outlines best practices for designing extractables studies, selecting analytical methods, and identifying unknown organic and inorganic compounds.
- USP ⟨1664⟩ (Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems): Focuses specifically on targeted and untargeted analytical methods to quantify actual leachables present in the marketed drug product over its shelf life.
3. Analytical Instrumentation: GC-MS, LC-MS, and ICP-MS Screening
Because extractables and leachables can span a massive molecular weight and polarity range, a multi-instrument analytical approach is mandatory:
- GC-MS (Gas Chromatography-Mass Spectrometry): Ideal for volatile and semi-volatile organic compounds (e.g., plasticizers, antioxidants, curing agents, residual solvents).
- LC-MS / LC-MS-MS (Liquid Chromatography-Mass Spectrometry): Essential for non-volatile organic compounds, oligomers, polar additives, and high-molecular-weight polymer degradation products.
- ICP-MS (Inductively Coupled Plasma Mass Spectrometry): Used to quantify elemental impurities and heavy metals (e.g., catalysts, colorants, glass delamination ions like aluminum, zinc, or lead).
Practical Gas Chromatography-Mass Spectrometry
Learn electron ionization, spectral library matching, and trace organic compound identification for pharmaceutical extractables testing.
Check Price on Amazon →ICP-MS in Pharmaceutical Analysis
Master elemental impurity screening per USP ⟨232⟩ / ⟨233⟩ and ICH Q3D guidelines for packaging metal migration studies.
Check Price on Amazon →4. Calculating the Analytical Evaluation Threshold (AET)
One of the most important concepts in E&L validation is the Analytical Evaluation Threshold (AET). The AET is the minimum concentration at which an analytical peak must be reported, investigated, and identified based on toxicological safety limits.
Any chromatographic peak falling below the AET is ignored; any peak at or above the AET must be chemically identified and evaluated for patient safety.
Where TTC is the Toxicological Threshold of Concern (e.g., 1.5 μg/day for a standard genotoxic threshold per ICH M7).
5. Toxicological Risk Assessments & Safety Thresholds (PQRI Guidelines)
Once extractables or leachables are identified and quantified, toxicologists evaluate their safety using frameworks established by the Product Quality Research Institute (PQRI) and ICH guidelines:
- Safety Concern Threshold (SCT): The threshold below which a leachable is considered so low in concentration that it presents negligible safety concerns (typically 0.15 μg/day for inhalation or parenteral drugs).
- Qualified Thresholds: Higher limits that require formal toxicological safety justification and structural alerts analysis based on lifetime human exposure risks.
Pharmaceutical Toxicology & Safety Assessment
Master safety evaluation thresholds (SCT), genotoxicity predictions (ICH M7), and human health risk assessments for drug impurities.
Check Price on Amazon →Analytical Method Validation Handbook
Validate your GC-MS and LC-MS leachable assay methods for specificity, linearity, limit of detection (LOD), and recovery.
Check Price on Amazon →6. E&L Validation Acceptance Parameter Matrix
| Study Phase | Primary Instrumentation | Key Acceptance Parameter | Regulatory Standard |
|---|---|---|---|
| Extractables Screening | GC-MS, LC-MS, ICP-MS | Exhaustive solvent profile; identification of all peaks above AET. | USP ⟨1663⟩ / PQRI |
| Leachables Stability | Targeted HPLC / LC-MS | Concentration over shelf life must remain below SCT / PDE limits. | USP ⟨1664⟩ / ICH Q1A |
| Elemental Impurities | ICP-MS | Heavy metal migration must comply with permitted daily exposure limits. | USP ⟨232⟩ / ICH Q3D |
| Glass Delamination | ICP-MS / Microscopy | Zero glass flakes or silica pitting in parenteral glass vials. | USP ⟨1663⟩ / FDA Guidance |
7. Interactive Analytical Evaluation Threshold (AET) Calculator
Calculate your required Analytical Evaluation Threshold (AET) for an extractables or leachables study based on Toxicological Threshold of Concern (TTC) and maximum daily patient dosing.
Analytical Evaluation Threshold (AET) Estimator
Regulatory Submissions & Drug Applications
Prepare airtight chemistry, manufacturing, and controls (CMC) dossier sections for container-closure systems and E&L validation.
Check Price on Amazon →ICH Q9 Quality Risk Management Handbook
Apply FMEA tools to evaluate container-closure interaction risks, elastomeric stopper degradation, and single-use bioprocess leaching.
Check Price on Amazon →8. Extractables & Leachables Validation Protocol Checklist
E&L Study Protocol & Execution Checklist
Single-Use Systems in Biopharma Validation
Master extractables testing for bioprocess bags, silicone tubing, sterile connectors, and single-use bioreactor assemblies.
Check Price on Amazon →Pharmaceutical Packaging Technology Handbook
Explore glass types (Type I borosilicate), polymer degradation, and elastomeric stopper formulation chemistry.
Check Price on Amazon →9. Top FDA Warning Letters & Filing Deficiencies: E&L Failures
Inadequate extractables and leachables data is a frequent trigger for FDA Complete Response Letters (CRLs) during new drug applications:
FDA & EMA Regulatory Deficiency Trends
- Incomplete Analytical Screening: Failing to test for non-volatile organic compounds or elemental impurities, relying solely on basic GC-MS without LC-MS or ICP-MS screening.
- Unjustified AET Reporting Limits: Setting analytical reporting thresholds too high, thereby missing toxic extractable peaks that fall below the screening radar.
- Ignoring Single-Use Bioprocess Extractables: Qualifying final drug products in glass vials but failing to evaluate extractables leaching from single-use mixing bags and silicone tubing used upstream in manufacturing.
- Lack of Real-Time Leachables Stability: Performing extractables screening on raw packaging materials but omitting formal leachable stability data on aged drug products over shelf life.
References & Regulatory Standards
- United States Pharmacopeia (USP) – General Chapters ⟨1663⟩ Assessment of Extractables and ⟨1664⟩ Assessment of Leachables.
- Product Quality Research Institute (PQRI) – Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products (OINDP).
- International Council for Harmonisation (ICH) – ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals.
- United States Food and Drug Administration (FDA) – Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics.
Disclaimers & Disclosures
Regulatory Disclaimer: This technical publication is intended for professional engineering and analytical chemistry educational purposes. Site-specific E&L studies, AET calculations, and toxicological evaluations must conform to approved facility Quality Management Systems (QMS) and applicable pharmacopeial standards.
Affiliate Disclosure: Contains affiliate links. As an Amazon Associate, this site earns from qualifying purchases, supporting ongoing technical publication costs.
No comments:
Post a Comment